Cynomolgus CD22 Protein

20.03.2013

Sino Biological Inc. liefert Cynomolgus CD22 Protein mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über Cynomolgus CD22 Protein lesen Sie bitte: http://www.sinobiological.com/CD22-Protein-a-1579.html

Produkt-Information von CD22 Protein

Synonym	CD22
Protein Construction	A DNA sequence encoding the cynomolgus CD22 (Met1-Arg686) was expressed with the Fc region of human IgG1 at the C-terminus.
Source	Cynomolgus
Expression Host	Human Cells

QC Testing von CD22 Protein

Purity	> 90 % as determined by SDS-PAGE	SDS-PAGE: CD22 protein
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	Ser 20
Molecular Mass	The recombinant cynomolgus CD22 is a disulfide-linked homodimer. The reduced monomer comprises 908 amino acids and has a calculated molecular mass of 102.1 KDa.The apparent molecular mass of the protein is approximately 117 KDa respectively in SDS-PAGE.
Formulation	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide von CD22 Protein

Storage	Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Verwandte Produkte & Themen von CD22 Protein

CD22 is a molecule belonging to the immunoglobulin superfamily, SIGLEC (sialic acid binding Ig-like lectin) family. It is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The CD22 cell-surface adhesion molecule is capable of modulating B lymphocyte antigen receptor (BCR)-mediated signals, as well as the generation of BCR-independent signals. CD22 is an inhibitory coreceptor of the B-cell receptor (BCR), and plays a critical role in establishing signalling thresholds for B-cell activation. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. Interaction of CD22 to ligands in trans can regulate both B-cell migration as well as the BCR signaling threshold. However, a more complex role for CD22 has recently emerged, including a central role in a novel regulatory loop controlling the CD19/CD21-Src-family protein tyrosine kinase (PTK) amplification pathway that regulates basal signaling thresholds and intensifies Src-family kinase activation after BCR ligation. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1. Thus, the CD19/CD22 loop may be a potential therapeutic target in autoimmune disease for modulating B cell signaling.

References

Sato S. et al., 1998, Semin Immunol. 10 (4): 287-97.
Walker JA. et al., 2008, Immunology. 123 (3): 314-25.
Nitschke L. 2009, Immunol Rev. 230 (1): 128-43.
Tedder TF. et al., 2005, Adv Immunol. 88: 1-50.
Fujimoto M. et al., 2007, J Dermatol Sci. 46 (1): 1-9.